Partner with us

Couple our expertise in diagnostics development with your expertise in therapeutics' development to speed time-to-market and improve patient benefit!


ICDD and personalized medecine

Drugs can have different effects on a given population. ICDD develops decision-making technologies to help its partners develop safer and more targeted drugs, in a patient-centered approach.

Partner with us to:

  • Facilitate clinical proof-of-concept through proper patient stratification and/or appropriate clinical management with adequate surrogate markers.
  • Improve health by ensuring that each patient gets the best treatment for him- or herself.
  • Reduce costs and time-to-market with shortened FDA approval time.

Interested in partnering with us? Contact us and ask for Nathalie.

CNS diseases

ICDD has developped the ADFlag® panel capable of segregating pre-sympatomatic stages of Alzheimer’s disease for patient stratification in clinical trials.

  • Contact us to use ADFlag® in your clinical trials.

ICDD has further identified specific signatures using mitochondrial behavior for AD, HD, Parkinson, and LRKK2 Parkinsonnism.

We are interested in partnering to:

  • Identify disease signatures in pilot cohorts of patients suffering from neuro-degenerative diseases.
  • Use our proprietary diagnostic tools to stratify patients in neurodegeneration clinical trials.
  • Develop companion diagnostics.

Patient-derived disease models

Let's work together to co-develop patient-derived disease models for your disease area with our proprietary technologies for disease-modifying drug selection.

Discovery of drug response elements

We are interested in industrial partnerships to identify molecular elements of patients' response and tolerance to your drugs with our proprietary models and technological platforms:

  • Mitostream®, a cellulomic platform.
  • Promembrane®, a proteomic platform.

These elements can then be used to co-develop a companion diagnostic test for your drugs to make sure they reach those patients who will benefit the most from it, in the most timely and cost-efficient manner.